Covaxin proven safe for children of 2-18 years age group in phase II/III study
Bharat Biotech International Ltd announced on June 17 that its COVID-19 vaccine Covaxin was safe, well-tolerated, and highly immunogenic in children and adolescents aged 2 to 18 years in a phase II/III study.
